α adrenergic receptor agon 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
  • ||||||||||  fentanyl citrate / Generic mfg.
    Review, Journal:  The New Stealth Drug on the Street: A Narrative Review of Xylazine as a Street Drug. (Pubmed Central) -  Jul 28, 2023   
    There are no rapid tests for xylazine, although there are specialty tests that can be ordered. Xylazine represents a major threat to street drug users and another challenge to emergency healthcare workers, first responders, and others who care for those who have taken this "new" street drug.
  • ||||||||||  Preclinical, Journal:  Evaluation of Vascular Pulse Contour Indices over the Physiological Blood Pressure Ranges in an Anesthetized Porcine Model. (Pubmed Central) -  Jan 4, 2022   
    Results from the pulse contour analysis of these waveforms demonstrated that Phenylephrine, as a post-synaptic alpha-adrenergic receptor agonist that causes vasoconstriction, produced a significant increment in the carotid BP parameters and heartrate. Due to the drug's effect, the PWVR and SEVR were significantly increased, whereas the RWTT, AIx index and ED index significantly decreased.Clinical Relevance- This experimental study provides the usefulness of the pulse contour analysis and estimation of various pulse waveform indexes for cardiovascular health screening and diagnosis.
  • ||||||||||  clonidine / Generic mfg.
    Journal:  Alpha-adrenergic receptor agonists prevent emotional hyperthermia. (Pubmed Central) -  Jul 29, 2021   
    In anesthetized rats, clonidine abolished the BAT sympathetic nerve discharges elicited through bicuculline-mediated disinhibition of the LHb. These results suggest that activation of central α-adrenergic receptors attenuates the process of emotional hyperthermia by reduction of BAT thermogenesis.
  • ||||||||||  [VIRTUAL] ISC83: A New Way Forward in Acquired Ptosis Treatment Industry Showcase Presented by RVL Pharmaceuticals, Inc. (Virtual Meeting Live Broadcast) -  Nov 11, 2020 - Abstract #AAO2020AAO_1727;    
    UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a novel, once-daily ophthalmic formulation of oxymetazoline, a direct-acting alpha adrenergic receptor agonist, which when administered to the eye, is believed to selectively target Müller muscle and elevate the upper eyelid. Upneeq is the first and only FDA-approved pharmacologic treatment indicated for the treatment of acquired blepharoptosis (ptosis, or droopy eyelid) in adults.
  • ||||||||||  [VIRTUAL] ISC36: A New Way Forward in Acquired Ptosis Treatment Industry Showcase Presented by RVL Pharmaceuticals, Inc. (Virtual Meeting Live Broadcast) -  Nov 11, 2020 - Abstract #AAO2020AAO_279;    
    UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a novel, once-daily ophthalmic formulation of oxymetazoline, a direct-acting alpha adrenergic receptor agonist, which when administered to the eye, is believed to selectively target Müller muscle and elevate the upper eyelid. Upneeq is the first and only FDA-approved pharmacologic treatment indicated for the treatment of acquired blepharoptosis (ptosis, or droopy eyelid) in adults.
  • ||||||||||  [VIRTUAL] ISC86: A New Way Forward in Acquired Ptosis Treatment Industry Showcase Presented by RVL Pharmaceuticals, Inc. (Virtual Meeting Live Broadcast) -  Nov 11, 2020 - Abstract #AAO2020AAO_96;    
    UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a novel, once-daily ophthalmic formulation of oxymetazoline, a direct-acting alpha adrenergic receptor agonist, which when administered to the eye, is believed to selectively target Müller muscle and elevate the upper eyelid. Upneeq is the first and only FDA-approved pharmacologic treatment indicated for the treatment of acquired blepharoptosis (ptosis, or droopy eyelid) in adults.